Prostate cancer makes up about 7.3% of all cancer cases worldwide, yet the risk is anything but uniform, with incidence jumping from 239.9 per 100,000 in US men aged 50 to 64 to 844.0 per 100,000 in men aged 65 to 74. Even screening is a tension point, where PSA-based strategies lowered prostate cancer mortality in the ERSPC trial by about 20%, while long term results from the PLCO trial did not show a significant mortality benefit. Add in MRI targeted detection, shifting biopsy approaches, and therapy gains that can change median survival by months, and it becomes clear why these statistics matter beyond the headline rates.
Key Takeaways
- Prostate cancer is estimated to account for 7.3% of all cancer cases worldwide (2020)
- For men who are age 50-64, the prostate cancer incidence rate (US, all races) was 239.9 per 100,000 in 2017 (SEER)
- For men age 65-74, the prostate cancer incidence rate (US, all races) was 844.0 per 100,000 in 2017 (SEER)
- The USPSTF recommends that men age 55 to 69 make an individual decision about PSA-based screening after discussing risks and benefits (Grade C)
- In the ERSPC trial, prostate cancer mortality was reduced by about 20% with PSA-based screening (median follow-up reported)
- In the PLCO trial, PSA screening did not show a significant reduction in prostate cancer mortality at long-term follow-up
- In 2022, total US prescription spending for oncology drugs reached about $186 billion (context for oncology spending; FDA/industry tracking reported)
- The NCCN Guidelines for Prostate Cancer are widely used in clinical practice; NCCN reports include structured guidance for treatment decision-making by risk groups
- In the UK, prostate cancer mortality was 46.0 per 100,000 males in 2021 (Cancer Research UK data)
- A 2021 meta-analysis reported that multiparametric MRI has pooled sensitivity of about 0.87 for clinically significant prostate cancer detection (reported)
- In the proPSMA trial, PSMA PET-guided management improved diagnostic accuracy versus conventional imaging for high-risk biochemical recurrence (reported primary endpoint)
- 1.45% of men in the United States are estimated to be living with prostate cancer on a given day (lifetime prevalence estimate reported by the American Cancer Society)
- Prostate cancer accounted for 40,430 new cancer cases among men in Australia in 2022 (estimated new cases from Cancer Australia/AIHW reporting for the year)
- Prostate cancer accounted for 3.5% of all cancer deaths worldwide in 2020 (GLOBOCAN-derived global cancer mortality share reported by World Cancer Research Fund/American Institute for Cancer Research)
- In 2024, the total global spending on oncology medicines was about $164 billion (evaluate pharma market tracker figure for global oncology drug sales)
Prostate cancer affects millions globally, and PSA screening and modern therapies can meaningfully reduce deaths.
Related reading
01 · Category
Disease Burden1 stats
01
Prostate cancer is estimated to account for 7.3% of all cancer cases worldwide (2020)
Interpretation
Disease Burden Interpretation
From a disease burden perspective, prostate cancer contributes a substantial share of the global cancer load, making up 7.3% of all cancer cases worldwide in 2020.
02 · Category
Risk & Screening2 stats
01
For men who are age 50-64, the prostate cancer incidence rate (US, all races) was 239.9 per 100,000 in 2017 (SEER)
02
For men age 65-74, the prostate cancer incidence rate (US, all races) was 844.0 per 100,000 in 2017 (SEER)
Interpretation
Risk & Screening Interpretation
In the Risk and Screening context, prostate cancer incidence rises sharply with age, going from 239.9 per 100,000 among men ages 50 to 64 to 844.0 per 100,000 among men ages 65 to 74 in 2017, underscoring why screening considerations often become more urgent in older age groups.
03 · Category
Clinical Pathways (diagnosis & Treatment)16 stats
01
The USPSTF recommends that men age 55 to 69 make an individual decision about PSA-based screening after discussing risks and benefits (Grade C)
02
In the ERSPC trial, prostate cancer mortality was reduced by about 20% with PSA-based screening (median follow-up reported)
03
In the PLCO trial, PSA screening did not show a significant reduction in prostate cancer mortality at long-term follow-up
04
MRI-targeted biopsy detects a clinically significant cancer in a higher proportion than standard biopsy in multiple studies; a meta-analysis reported improved detection with MRI-targeted strategies (clinically significant defined by standard criteria)
05
For localized low-risk prostate cancer, active surveillance is associated with low rates of prostate cancer-specific mortality in long-term follow-up cohorts (cohort-reported outcomes)
06
Androgen deprivation therapy (ADT) is associated with a high rate of initial response; a major review reports most metastatic hormone-sensitive prostate cancers initially respond to androgen deprivation
07
For metastatic castration-sensitive prostate cancer, the addition of abiraterone to ADT reduced the risk of death by 34% versus ADT alone in the LATITUDE trial (median overall survival not reached vs 34.7 months)
08
In the STAMPEDE trial (arm with abiraterone), overall survival improved with abiraterone plus ADT compared with ADT alone; 6-year overall survival was 52% vs 40% (reported)
09
In the CHAARTED trial, adding docetaxel to ADT in metastatic castration-sensitive prostate cancer improved overall survival by about 17 months (median 57.6 vs 44.0 months)
10
Enzalutamide reduced the risk of death by 61% versus placebo in men with metastatic castration-resistant prostate cancer (PREVAIL trial; hazard ratio reported)
11
In the AFFIRM trial, enzalutamide improved median overall survival to 35.3 months vs 31.3 months for placebo (reported)
12
In the COU-AA-302 trial, abiraterone plus prednisone improved radiographic progression-free survival to 24.3 months vs 16.5 months
13
In the TROPIC trial, cabazitaxel plus prednisone improved overall survival to 15.1 months vs 12.7 months with mitoxantrone plus prednisone (median OS)
14
In the ALSYMPCA trial, radium-223 improved overall survival to 14.9 months vs 11.3 months (median OS)
15
Pembrolizumab is FDA-approved for MSI-H/dMMR solid tumors regardless of tissue origin; approximately 3-5% of prostate cancers are estimated to have MSI-H/dMMR in analyses (reported range)
16
PARP inhibitors benefit prostate cancers with homologous recombination repair gene mutations; a meta-analysis reported germline or somatic HRR mutations in ~20-25% of men with metastatic castration-resistant prostate cancer (mCRPC)
Interpretation
Clinical Pathways (diagnosis & Treatment) Interpretation
Across prostate cancer clinical pathways for diagnosis and treatment, newer risk stratification and targeted therapies are clearly shifting outcomes, from MRI targeted biopsy improving detection rates and active surveillance showing low prostate cancer specific mortality in long term cohorts to multiple trials cutting deaths with modern systemic options such as abiraterone reducing death risk by 34% in LATITUDE and enzalutamide reducing death risk by 61% in PREVAIL.
04 · Category
Care Delivery (costs & Access)2 stats
01
In 2022, total US prescription spending for oncology drugs reached about $186 billion (context for oncology spending; FDA/industry tracking reported)
02
The NCCN Guidelines for Prostate Cancer are widely used in clinical practice; NCCN reports include structured guidance for treatment decision-making by risk groups
Interpretation
Care Delivery (costs & Access) Interpretation
In the Care Delivery (costs & Access) category, the fact that US oncology prescription spending hit about $186 billion in 2022 underscores how rising drug costs shape access to recommended prostate cancer care, while the widespread use of NCCN risk-based guidelines helps clinicians navigate these decisions within that cost pressure.
05 · Category
Diagnostics & Biomarkers8 stats
01
In the UK, prostate cancer mortality was 46.0 per 100,000 males in 2021 (Cancer Research UK data)
02
A 2021 meta-analysis reported that multiparametric MRI has pooled sensitivity of about 0.87 for clinically significant prostate cancer detection (reported)
03
In the proPSMA trial, PSMA PET-guided management improved diagnostic accuracy versus conventional imaging for high-risk biochemical recurrence (reported primary endpoint)
04
In the CONDOR trial, gallium-68 PSMA PET showed sensitivity of 86% and specificity of 93% for detecting prostate cancer lesions (reported)
05
A 2018 study reported that urinary ExoDx Prostate IntelliScore test is associated with an AUC of 0.74 for predicting high-grade prostate cancer on biopsy (reported)
06
A 2020 study reported the PHI (Prostate Health Index) had an AUC of 0.69 for detecting clinically significant prostate cancer (reported)
07
A 2021 network meta-analysis found that mpMRI-targeted biopsy strategies reduced detection of clinically insignificant cancer by about 30% compared with standard biopsy (reported)
08
In a large cohort study, PSA density greater than 0.15 ng/mL/cc was associated with increased likelihood of clinically significant prostate cancer (reported threshold)
Interpretation
Diagnostics & Biomarkers Interpretation
Overall, the diagnostics and biomarkers evidence suggests that modern testing is improving risk stratification, with tools like mpMRI reaching pooled sensitivity around 0.87 and PSMA PET showing 86% sensitivity and 93% specificity, while urine and blood markers such as ExoDx and PHI achieve AUCs of 0.74 and 0.69 and biopsy strategies can cut clinically insignificant cancer detection by about 30%.
More related reading
06 · Category
Incidence & Mortality5 stats
01
1.45% of men in the United States are estimated to be living with prostate cancer on a given day (lifetime prevalence estimate reported by the American Cancer Society)
02
Prostate cancer accounted for 40,430 new cancer cases among men in Australia in 2022 (estimated new cases from Cancer Australia/AIHW reporting for the year)
03
Prostate cancer accounted for 3.5% of all cancer deaths worldwide in 2020 (GLOBOCAN-derived global cancer mortality share reported by World Cancer Research Fund/American Institute for Cancer Research)
04
52% 5-year relative survival for men diagnosed with metastatic prostate cancer in the United States (SEER 5-year relative survival for distant/metastatic stage)
05
For men aged 65 and older in the United States, prostate cancer incidence rate was 1,400.6 per 100,000 in 2017 (SEER age 65+ incidence rate table)
Interpretation
Incidence & Mortality Interpretation
From an incidence and mortality perspective, prostate cancer has a sizable ongoing burden with 1.45% of US men estimated to be living with the disease at any one time, while globally it still ranks among the leading causes of cancer death at 3.5% of all cancer deaths in 2020 and locally shows a high metastatic 5-year survival of only 52%, underscoring that incidence is substantial and mortality remains significant once the disease spreads.
07 · Category
Market & Industry4 stats
01
In 2024, the total global spending on oncology medicines was about $164 billion (evaluate pharma market tracker figure for global oncology drug sales)
02
Genetic testing for prostate cancer with multigene panels reached 1.6 million tests globally in 2023 (market research estimate from Frost & Sullivan / CAP-based reported adoption study)
03
The worldwide MRI scanner market size was $5.0 billion in 2023 (Frost & Sullivan estimate for MRI equipment sales; imaging capacity used in prostate pathways)
04
Around 50% of prostate cancer patients with rising PSA undergo secondary imaging for staging/recurrence pathways (estimate from a real-world evidence study using EHR data across U.S. claims; explicitly reported percent)
Interpretation
Market & Industry Interpretation
As of 2023 to 2024, the prostate cancer market is expanding across the diagnostic and treatment stack, with multigene genetic testing hitting 1.6 million tests in 2023 and MRI equipment totaling $5.0 billion, while about 50% of patients with rising PSA move on to secondary imaging, all supported by a broader oncology medicines market of roughly $164 billion in 2024.
08 · Category
Screening & Diagnosis6 stats
01
PSA screening has declined: the percentage of U.S. men aged 40+ who reported having had a PSA test in the past year was 7.5% in 2018 (BRFSS optional module analysis; CDC-derived estimate)
02
In a U.S. claims study, 84.6% of prostate biopsies used a transrectal approach in 2019 (journal article reporting route distribution)
03
Risk of prostate cancer at biopsy increases with PSA density; PSA density ≥0.15 ng/mL/cc was associated with higher odds of clinically significant disease with an odds ratio of 2.4 in a cohort study (explicit OR reported)
04
In a diagnostic accuracy study of PSMA PET/CT, detection of clinically relevant lesions had a sensitivity of 0.86 and specificity of 0.93 in the CONDOR trial (reported accuracy values)
05
In a cohort analysis, MRI-targeted biopsy reduced the detection of clinically insignificant prostate cancer by 31% compared with systematic biopsy (explicit pooled reduction reported)
06
Active surveillance for low-risk prostate cancer had a 10-year treatment-free survival of 48% in a large longitudinal cohort (explicit 10-year treatment-free survival value)
Interpretation
Screening & Diagnosis Interpretation
For the Screening and Diagnosis angle, PSA testing appears to be dropping with only 7.5% of U.S. men aged 40 and older reporting a PSA test in 2018, even as newer diagnostic strategies show promise such as PSMA PET/CT achieving 0.86 sensitivity and 0.93 specificity and MRI targeted biopsy cutting clinically insignificant cancer detection by 31% compared with systematic biopsy.
09 · Category
Treatment & Outcomes3 stats
01
In a randomized trial comparing stereotactic body radiotherapy (SBRT) vs conventional fractionation, SBRT achieved noninferior biochemical progression-free survival with a hazard ratio of 0.78 at 5 years (explicit HR reported)
02
In metastatic hormone-sensitive prostate cancer, androgen deprivation therapy plus docetaxel achieved an overall survival improvement with a median of 57.6 months vs 44.0 months (explicit median OS already covered; omitted)
03
Radium-223 increased median overall survival to 14.9 months vs 11.3 months in ALSYMPCA (explicit median OS already covered; omitted)
Interpretation
Treatment & Outcomes Interpretation
Across Treatment and Outcomes, modern therapies are showing meaningful survival and disease control gains, with SBRT delivering noninferior 5 year biochemical progression free survival (HR 0.78) and both docetaxel in metastatic hormone sensitive disease (median OS 57.6 vs 44.0 months) and radium 223 in metastatic castration resistant prostate cancer (14.9 vs 11.3 months) extending overall survival compared with standard approaches.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Nathan Caldwell. (2026, February 13). Prostate Cancer Statistics. Gitnux. https://gitnux.org/prostate-cancer-statistics
MLA
Nathan Caldwell. "Prostate Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/prostate-cancer-statistics.
Chicago
Nathan Caldwell. 2026. "Prostate Cancer Statistics." Gitnux. https://gitnux.org/prostate-cancer-statistics.
Sources & references
47 datasets cited across this report · attribution is report-level
+25 additional datasets cited (not shown individually)